1. A molecular perspective of CTLA-4 function. Teft WA, Kirchhof MG, Madrenas J.Annu Rev Immunol. 2006;24:65-97; 2. The B7-CD28 superfamily. Sharpe AH, Freeman GJ.Nat Rev Immunol. 2002 Feb;2(2):116-26; 3. The emerging role of CTLA4 as a ...
Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011 Nov 25;11(12):852-63. Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosi...
1.A molecular perspective of CTLA-4 function. Teft WA, Kirchhof MG, Madrenas J.Annu Rev Immunol. 2006;24:65-97. 2.The B7-CD28 superfamily. Sharpe AH, Freeman GJ.Nat Rev Immunol. 2002 Feb;2(2):116-26. 3.The emerging role of CTLA4 as a cell-extrinsic regulator of T cell response...
[2] Tang F., et al. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? Cell & Bioscience 8: 30 (2018).CTLA-4人源化小鼠，助力肿瘤研究 品系背景：C57BL/6N 品系构建策略：在小鼠基因组上的Ctla-4基因位点敲入人源CTLA-4胞...
1. A molecular perspective of CTLA-4 function. Teft WA, Kirchhof MG, Madrenas J.Annu Rev Immunol. 2006;24:65-97. 2. The B7-CD28 superfamily. Sharpe AH, Freeman GJ.Nat Rev Immunol. 2002 Feb;2(2):116-26. 3. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell re...
图片来源:Cell Press 目前,全球已有3款CTLA-4抗体或融合蛋白上市,分别是2005年上市的Orencia (abatacept),2011年上市的Nulojix (belatacept)以及Yervoy(ipilimumab),2025年3种上市药物的预测销量可达60亿美元。共有96个涉及CTLA-4抗体及融合蛋白的在研药物,其中tremelimumab是市场认为最有可能下一个上市的CTLA-4产品。
免疫系统中,负向调控T淋巴细胞激活的因子称为免疫检查点分子,免疫检查点分子在限制机体免疫系统过度激活、维持机体免疫稳态过程中发挥重要作用。细胞毒性T淋巴细胞抗原4(Cytotoxic T lymphocyte antigen 4, CTLA4)和程序性细胞死亡1(Programmed cell death 1, PD-1)是最受关注且最有效的T细胞免疫检查点分子。(图-2)...
CTLA-4和CD28均为免疫球蛋白超家族成员,二者与相同的配体CD86(B7-2)和CD80(B7-1)结合。CTLA-4的免疫调控功能的关键体现在控制CD4+FoxP3-、CD8+T细胞以及调节性T细胞(Treg)。CTLA-4能够中止激活的T细胞的反应(T cell response)以及介导Treg的抑制功能。目前的研究表明CTLA-4抑制T细胞的反应主要是通过两种途径: ...
除此之外,ICIs类药物还包括CTLA-4单抗(ipilimumab、tremelimumab)、淋巴细胞活化基因3(LAG-3)单抗(relatlimab)、T细胞免疫球蛋白(T cell immunog-lobulin)和免疫受体酪氨酸抑制基序(ITIM)结构域单抗(tiragolumab)等。 相较于PD-1/PD-L1抑制剂单药在肿瘤治疗领域的广泛应用,CTLA-4抑制剂在双免疫疗法中的应用丰富...
[2] Tang F., et al. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? Cell & Bioscience 8: 30 (2018). CTLA-4人源化小鼠,助力肿瘤研究 品系背景:C57BL/6N 品系构建策略: ...